References in periodicals archive ?
NSAID classification Non-selective inhibition Acetic acid Proprionic acid Fenamate derivatives derivatives derivatives * Diclofenac * Fenoprofen * Meclofenamate * Etodolac * Flurbiprofen * Mefenamic acid * Indomethacin * Ibuprofen * Sulindac * Ketoprofen * Tolmetin * Naproxen * Oxaprozin Naphthyl alkanone Salicylates * Nabumetone * Aspirin * Diflunisal * Choline magnesium trisalicylate * Salicylate Enolic acid derivatives * Piroxicam * Meloxicam Selective COX-2 inhibition * Celecoxib * Rofecoxib Table 9.
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, doubledummy, Phase IV study in Korean patients.
Other relatively safer drugs, such as nabumetone, low-dose ibuprofen (< 1600 mg/24 hours), and etodolac, are usually listed together with similar effects.
Consider the case of nabumetone (brand name: Relafen), a nonsteroidal anti-inflammatory drug (NSAID), approved by the FDA for the treatment of rheumatoid arthritis and osteoarthritis in 1992.
Those on naproxen (topical COX-1 and -2 inhibitor) or nabumetone (COX-1 and -2 inhibitor) had relapses associated with intestinal inflammation.
Etodolac, nabumetone, and meloxicam are slightly COX-2 selective.
This prompted enquiries regarding the patient's drug history, and it was found that the patient had recently been prescribed nabumetone, a nonsteroidal anti-inflammatory agent [Relafen (Relifex in the UK); SmithKline Beecham].
has received approval from the United States Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 mg and 750 mg.
36 which included income from a payment to settle all Nabumetone patent litigation that increased net income by $6.
Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nabumetone Tablets USP, 500 mg and 750 mg.
09 per share from the receipt of a $10 million payment to settle all patent infringement litigation related to Nabumetone and the receipt of a $3.
9 million for nabumetone, and lower inventory write-offs, in addition to the other factors discussed above.
The class includes all persons or entities who purchased Relafen or its generic alternative, nabumetone, from September 1, 1998 to June 30, 2003.
announce a Proposed Class Action Settlement on behalf of Consumers and Third Party Payors involving the purchase of Relafen(R) or its generic alternative nabumetone dispensed pursuant to prescriptions.
Full year guidance includes the receipt of a $10 million payment to settle all litigation relating to Nabumetone and the receipt of a $3.
Thesaurus browser ?
- N. Y. Stock Exchange
- Nabalus alba
- Nabalus serpentarius
- nabothian cyst
- nabothian follicle
- nabothian gland
- nacreous cloud
- NADA daiquiri
- Nadine Gordimer
- Naegele's rule
- Naemorhedus goral
- Nag Hammadi
Full browser ?
- Nabuco, Joaquim
- Nabulsi, Sulayman Al-
- Nabunturan National Comprehensive High School
- NACA 0012 airfoil
- NACA 0015
- NACA airfoil
- NACA cowling